- Home
- TCMD vs ACRS Comparison
TCMD vs ACRS Comparison
Compare TCMD & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCMD | ACRS |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 314.2M |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TCMD | ACRS |
|---|---|---|
| Price | $30.48 | $2.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $27.00 | $9.75 |
| AVG Volume (30 Days) | 322.3K | ★ 901.0K |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.66 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $311,513,000.00 | $15,742,000.00 |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | $39.73 | ★ N/A |
| Revenue Growth | ★ 9.28 | N/A |
| 52 Week Low | $8.61 | $1.05 |
| 52 Week High | $31.13 | $3.48 |
Technical Indicators
Market Signals| Indicator | TCMD | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 41.40 |
| Support Level | $29.11 | $2.50 |
| Resistance Level | $30.87 | $2.81 |
| Average True Range (ATR) | 1.05 | 0.16 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 86.91 | 25.23 |
Price Performance
Historical ComparisonAbout TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.